4CPS-170 Evaluation of zoledronic acid in the treatment of bone diseases with high risk of fractures

BACKGROUND: Zoledronic acid (ZOL) administered as a 5 mg intravenous infusion anually is indicated for the treatment of bone diseases such as Paget disease and osteoporosis with a high risk of fracture. It is strongly advised that patients treated with ZOL receive adequate calcium and vitamin D (cal...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Eur J Hosp Pharm
Main Authors: Puivecino-Moreno, C, Alcalá-Soto, A, Vázquez-Vela, V, Jiménez-Pichardo, L, Varas-Pérez, A, Marín-Ariza, I, Gómez-de-Travecedo-Calvo, MT
Format: Artigo
Sprog:Inglês
Udgivet: BMJ Group 2018
Fag:
Section 4: Clinical pharmacy services
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535356/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.260
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker